Abbott Laboratories (NYSE: ABT) heads into Monday’s session with investors weighing a busy set of headlines—ranging from a fresh dividend hike to a high-profile acquisition in cancer diagnostics, plus regulatory attention around certain FreeStyle Libre sensors.
ABT closed Friday, Dec. 12 at $125.46, up 1.77%, marking a third straight day of gains, though it remains about 11% below its 52‑week high. MarketWatch
Below is what market watchers are likely to focus on before the opening bell on Monday, Dec. 15, 2025.
The quick snapshot investors are starting with
- Last close: ABT finished $125.46 on Friday, Dec. 12. MarketWatch
- 52‑week context: Market data cited ABT’s 52‑week high at $141.23 (March 4), putting the stock roughly 11.17% below that peak. MarketWatch
- Volume: Friday volume was reported around 4.8 million shares, below a cited 50‑day average of 6.3 million—often read as a “steady, not panicky” tape. MarketWatch
This matters because Monday’s opening trade may reflect how investors rank the week’s biggest catalysts: shareholder returns (dividend), risk headlines (device correction / FDA alert), and longer-cycle strategy (Exact Sciences deal).
Headline 1: Abbott just raised its dividend again
On Dec. 12, Abbott announced its board approved an increase in the quarterly common dividend to $0.63 per share, a 6.8% increase. Abbott MediaRoom
Key details investors typically track:
- Payable date:Feb. 13, 2026
- Record date:Jan. 15, 2026 Abbott MediaRoom
- Abbott said this marks its 54th consecutive year of dividend growth and the 408th consecutive quarterly dividend paid since 1924. Abbott MediaRoom
At Friday’s close (~$125.46), the new run‑rate dividend implies an annualized payout of $2.52, or roughly a ~2.0% yield (before taxes and assuming the payout remains unchanged). MarketWatch+1
Why it can matter on Monday: A dividend raise doesn’t usually change long-term fundamentals overnight, but it can reinforce Abbott’s “defensive growth + income” positioning—especially for investors screening for consistency of payouts and balance-sheet confidence.
Headline 2: FreeStyle Libre 3 sensor correction and FDA attention
One of the most closely watched Abbott headlines into mid‑December is the company’s medical device correction involving certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors in the U.S.
What Abbott said
Abbott said internal testing found some sensors may provide incorrect low glucose readings, which—if not detected—could contribute to incorrect treatment decisions. Abbott MediaRoom
The company’s notice included several numbers investors tend to focus on:
- Roughly 3 million sensors in the U.S. from the affected production line (with Abbott estimating about half were already used or expired). Abbott MediaRoom
- Reports of 736 severe adverse events globally (57 in the U.S.) and seven deaths (Abbott said none in the U.S.) “potentially associated” with the issue. Abbott MediaRoom
- Abbott said it identified and resolved the manufacturing issue and does not expect significant supply disruptions, while continuing production to support replacements and new orders. Abbott MediaRoom
Reuters also emphasized Abbott described this action as a correction, not a recall, and pointed users to the company’s verification and replacement process. Reuters
What regulators said
The FDA issued an Early Alert about a “potentially high-risk issue” involving certain Libre sensors that could provide incorrect low readings, advising patients to stop using affected sensors and check device details. U.S. Food and Drug Administration
What investors may watch next
Going into Monday, Wall Street’s core questions are typically less about the headline itself (which has been in the market since late November) and more about the second-order impacts:
- Cost of remediation (replacements, customer support, logistics) and whether Abbott quantifies any near‑term financial hit in future updates. Abbott MediaRoom
- Reputation and competitive dynamics in continuous glucose monitoring (CGM)—especially as the company also pushes broader consumer access through its Lingo product (more below). Abbott MediaRoom+1
- Regulatory follow-through—whether the FDA issues additional communications or classifications that shape sentiment beyond the initial alert. U.S. Food and Drug Administration
Headline 3: The Exact Sciences acquisition is a major strategic swing
Abbott’s biggest corporate strategy headline into year‑end is its announced agreement to acquire Exact Sciences (NASDAQ: EXAS), the company behind Cologuard (at-home colorectal cancer screening) and Oncotype DX (precision oncology testing).
Deal terms and timing
Abbott and Exact Sciences announced a definitive agreement under which Abbott would pay $105 per share in cash, representing about $21 billion in equity value and about $23 billion enterprise value (including debt). Abbott MediaRoom+1
Abbott said its financing contemplates absorbing roughly $1.8 billion of Exact’s estimated net debt, and the transaction is expected to close in Q2 2026, subject to shareholder and regulatory approvals and other customary conditions. Abbott MediaRoom+1
Why Abbott is doing it
Abbott framed the acquisition as entry into “fast‑growing cancer diagnostics segments,” adding a new growth vertical to its diagnostics franchise. Abbott MediaRoom
Reuters noted the move comes as Abbott’s diagnostics business has faced headwinds from declining COVID-19 testing revenues, making expansion into large oncology markets more strategically attractive. Reuters
The key investor debate: long-term opportunity vs. near-term dilution
This is where “analysis” becomes most important for Monday’s read-through:
- Reuters reported the deal is expected to be dilutive to Abbott’s adjusted earnings through 2027, and cited commentary that raised questions about the strategic fit given Abbott “lacks an existing oncology segment,” potentially adding near-term execution risk. Reuters
- On the other hand, Abbott said the acquisition would be “immediately accretive to Abbott’s revenue growth and gross margin,” and projected Exact would generate more than $3 billion in revenue in 2025, with Abbott’s total diagnostics sales expected to exceed $12 billion annually post-close. Abbott MediaRoom+1
Why it matters before the Dec. 15 open: The deal isn’t new news (announced Nov. 20), but it continues to shape how investors value ABT’s 2026–2028 earnings trajectory—especially when paired with near-term headline risk in diabetes devices.
Headline 4: Baby formula litigation and the “legal shield” push
Another headline that resurfaced prominently late last week: Abbott is reportedly pressing policymakers for protection tied to lawsuits over preterm infant formula and necrotizing enterocolitis (NEC).
A Bloomberg-reported story (republished by Insurance Journal) described Abbott warning it could stop making one of the two most widely used preemie formulas unless the company receives stronger legal protection, and said Abbott has been pushing for a law that could throw out pending suits and shield it from future ones. Insurance Journal
The same reporting notes:
- Abbott has publicly disputed the claims and argued research does not support allegations against it. Insurance Journal
- The broader litigation landscape has included mixed outcomes, including major verdicts referenced in Reuters coverage and court rulings on expert testimony and case progression. Reuters+1
Why it matters on Monday: Even if the immediate financial impact is hard to model, litigation and policy risk can change investor sentiment quickly—especially when it intersects with politically sensitive markets like infant nutrition and broader concerns about supply fragility (a theme policymakers remember vividly from the baby formula shortage period). Insurance Journal+1
Headline 5: Lingo expands—supporting the consumer “biowearables” story
Abbott is also trying to broaden the story around glucose monitoring beyond traditional diabetes care.
On Dec. 8, Abbott said its Lingo over-the-counter CGM and app is now available for Android, expanding access beyond iOS. Abbott MediaRoom
And earlier in the rollout, Axios reported Walmart would become the first U.S. retailer to sell an over-the-counter CGM in physical stores as Lingo rolled out to 3,500+ locations, signaling continued mass-market expansion of metabolic tracking. Axios
Why it matters now: The Lingo push is part of Abbott’s longer-term narrative that CGMs can become a broader consumer category. But it’s arriving at a time when the Libre correction is also in headlines—making “trust + reliability” and the strength of Abbott’s support response especially important to investor confidence. Abbott MediaRoom+1
Where guidance and forecasts stand heading into Monday
What Abbott guided
In its Q3 2025 update, Abbott reaffirmed its full-year 2025 outlook, including organic sales growth guidance and a narrowed adjusted diluted EPS range (as stated in its Q3 release materials). Abbott MediaRoom+1
What analysts are modeling
A Zacks commentary carried by Nasdaq (dated Dec. 8) cited expectations for Abbott’s next earnings report of about $1.50 EPS on roughly $11.79 billion in revenue (with additional full-year consensus figures also referenced). Nasdaq
Separately, “street” forecast aggregators continue to show broadly positive sentiment:
- MarketBeat’s summary indicates a consensus view around “moderate buy” and cites a projected upside (based on analyst targets) of roughly 17%. MarketBeat
- A MarketWatch analyst-estimates page snapshot lists an average target price around $145 and an average recommendation of Overweight, though exact numbers vary by vendor and update frequency. MarketWatch
- Barclays reiterated an Overweight view and raised its price target to $162 in mid‑October, arguing the post‑earnings pullback was an opportunity and expecting improvement into 2026 and beyond. TipRanks
How to read this going into Dec. 15: In practical terms, the “forecast” picture for ABT into Monday looks like this: analysts generally see upside over a 12‑month window, but the market is actively discounting near‑term uncertainty—particularly around the Exact deal’s earnings dilution timeline and the Libre correction headline risk. Reuters+2Abbott MediaRoom+2
Corporate governance and insider paperwork: small, but on the radar
These items rarely move the stock alone, but they’re part of the weekend news flow:
- Abbott filed an 8‑K noting Nita Ahuja, M.D. was appointed to the board and that Abbott amended its bylaws to increase board size to 13 directors (from 12), effective Dec. 12, 2025. Stock Titan
- A Form 4 reflected a reported gift of 1,536 shares by an Abbott vice president (a non-open-market transaction), per Refinitiv/filing summaries. TradingView+1
What could move ABT when the market opens Monday
Heading into Dec. 15, ABT price action is most likely to respond to one of three things:
- Any new incremental update (media, FDA, or Abbott) on the Libre 3 / Libre 3 Plus correction beyond what’s been disclosed since Nov. 24 and the early December FDA alert. Abbott MediaRoom+1
- Deal-related developments around Exact Sciences—anything affecting timing, financing perception, or integration narrative (even before close in Q2 2026). Abbott MediaRoom+1
- Policy/litigation headlines tied to preemie formula NEC lawsuits and the reported push for protections—particularly if lawmakers weigh in publicly. Insurance Journal+1
Meanwhile, the dividend increase may provide a mild supportive backdrop for income-focused demand, especially in volatile tape conditions. Abbott MediaRoom
The dates to keep on your calendar after the Dec. 15 open
- Dividend record date:Jan. 15, 2026 (per Abbott) Abbott MediaRoom
- Dividend payable date:Feb. 13, 2026 (per Abbott) Abbott MediaRoom
- Next earnings timing: Several market calendars estimate Abbott’s next earnings report around late January 2026 (often listed as Jan. 28, 2026, but not confirmed by Abbott in those listings). MarketBeat+1
- Exact Sciences deal close target:Q2 2026 (subject to approvals). Abbott MediaRoom+1
